Amarin reported $119.52M in Cash and Equivalent for its fiscal quarter ending in March of 2025.


Cash And Equivalent Change Date
AbbVie USD 5.18B 349M Mar/2025
Alnylam Pharmaceuticals USD 1.11B 94.03M Jun/2025
Amarin USD 119.52M 1.51M Mar/2025
AstraZeneca USD 7.06B 1.83B Jun/2025
DBV Technologies USD 103.21M 103.21M Jun/2025
GlaxoSmithKline GBP 3.6B 865M Jun/2025
Halozyme Therapeutics USD 61.86M 114.47M Jun/2025
Ionis Pharmaceuticals USD 297.3M 33.11M Jun/2025
Neurocrine Biosciences USD 264M 69.9M Jun/2025
Novartis USD 6.66B 410M Jun/2025